Dosing and administration: Simple dosing schedule

Xolair® has a simple dosing

Administered subcutaneously using a pre-filled syringe*

Xolair® has a simple dosing schedule

The approved dose of Xolair® is 2 x 150 mg injections. Patients should be observed following injection1

Xolair® should be administered by a healthcare professional every 4 weeks1

Prescribers are advised to regularly check the need to continue treatment**1

Well established safety profile and more than 819,419 patient-years experience***1–3


Prescribing Xolair® in CSU, there is:

No need to determine baseline lgE

No need to calculate the dose based on patient's body weight

*Xolair® is also available as a lyophilized formulation

**Clinical trial experience of long-term treatment beyond 6 months in CSU is limited.

***This patient population includes patients suffering from Chronic Spontaneous Urticaria (CSU) as well as Severe Allergic Asthma (SAA).

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

Model is a hypothetical patient profile, for illustrative purposes only

References: 1. Xolair® Summary of Product Characteristics. 2. Periodic Safety Update Report (PSUR) version 22. 3. Xolair® US Product information. 4. Maurer M, et al. N Engl J Med 2013;368:924-935.

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma